Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Thursday, December 2, 2021

What We Might Learn from COVID-19

The COVID-19 pandemic has had a profound effect on communities and MEBO community is not an exception. Planned diagnostic and therapeutic studies were put on hold or transitioned from collecting new data to just analyzing the data. Any disadvantage, however, can be turned into an advantage. COVID-19 can help us to learn more about FMO3, distorted sense of smell, gut dysbiosis and other conditions contributing to malodor syndromes. Observations about COVID-19/vaccine reactogenicity in the MEBO community could help to attract researchers' interest and design better interventions against malodor conditions. 

The COVID-back-to-normal study (registered as NCT04832932) follows about 1000 participants from different online and offline communities and compares their susceptibility to SARS-CoV-2 infection, reactions to vaccines, COVID- and post-COVID symptoms. 

Preliminary results suggest there are interesting differences between the MEBO community and others. 

It is not unexpected. This figure from a recent article in Nature Medicine shows that FMO3 is one of the genes whose expression correlates with ACE2, the gene employed by  SARS-CoV-2 for cellular entry. A few other potential links between TMAU and COVID-19 are discussed in the latest Aurametrix blog

Your observations, hypotheses and comments are most welcome.

Short URLs for the survey :  (in English) 

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization


Post a Comment